Pfizer (NYSE:PFE) Stock Price Up 1.4% – Should You Buy?

Pfizer Inc. (NYSE:PFE) traded up 1.4% on Thursday . The company traded as high as $26.20 and last traded at $26.1840. 49,975,867 shares were traded during mid-day trading, an increase of 18% from the average session volume of 42,435,234 shares. The stock had previously closed at $25.81.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Q2 earnings beat expectations: Pfizer reported adjusted EPS of $0.77 versus the $0.68 consensus estimate, while revenue of $15.03 billion exceeded expectations of $14.40 billion. Strong demand for Eliquis and other non-COVID products helped offset weaker COVID-related sales. Pfizer beats quarterly profit estimates on strong demand for blood thinner Eliquis
• Positive Sentiment: Raised outlook and deeper cost savings: Management increased the low end of its 2026 revenue guidance and raised its cost-reduction target to $2.5 billion. Investors viewed the savings program and continued non-COVID growth as evidence that Pfizer’s recovery is progressing despite the post-pandemic revenue reset. Pfizer Q2 Earnings Call Highlights Non-COVID Growth and Cost Cuts
• Positive Sentiment: Pipeline updates add longer-term support: Pfizer and BioNTech reported an update on a next-generation pediatric COVID booster study, while Pfizer completed an early Phase 1 study of PF-07328948. The company also reported positive Phase 3 LITFULO data in vitiligo, providing additional potential growth catalysts. Pfizer and BioNTech Lock In Next-Gen Pediatric COVID Booster Edge
• Positive Sentiment: Income appeal remains a factor: Recent coverage highlights Pfizer’s high dividend yield and its dividend increase, which may attract income-oriented investors while the company rebuilds its product portfolio. After Q2 Earnings, Is Pfizer or Merck the Smarter Dividend Play?
• Neutral Sentiment: Analyst views remain mixed: RBC Capital maintained a Hold rating, indicating that improved operating performance has not fully removed concerns about Pfizer’s longer-term growth profile. RBC Capital Remains a Hold on Pfizer
• Negative Sentiment: COVID and obesity setbacks remain risks: Revenue from Pfizer’s COVID pill reportedly fell sharply, while challenges surrounding its obesity program and upcoming patent expirations could limit growth. Investors will need evidence that newer products and pipeline candidates can replace declining legacy revenue. Pfizer Covid Pill Revenue Plunges 95%. The Stock Is Rising Anyway.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on PFE shares. Royal Bank Of Canada upgraded Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 price objective on the stock in a research note on Tuesday, June 9th. HSBC downgraded Pfizer from a “buy” rating to a “hold” rating and cut their target price for the company from $32.00 to $28.00 in a research report on Monday, July 6th. Cantor Fitzgerald restated a “neutral” rating and issued a $27.00 price target on shares of Pfizer in a research report on Monday, July 6th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Pfizer in a research note on Monday. Finally, Guggenheim cut their price objective on shares of Pfizer from $36.00 to $35.00 and set a “buy” rating for the company in a research report on Monday, July 13th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fourteen have given a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $28.50.

Pfizer Stock Performance

The company has a current ratio of 1.25, a quick ratio of 0.94 and a debt-to-equity ratio of 0.67. The company has a market cap of $149.23 billion, a P/E ratio of 34.45 and a beta of 0.34. The company has a 50 day moving average price of $25.01 and a 200-day moving average price of $26.16.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share for the quarter, topping the consensus estimate of $0.68 by $0.09. Pfizer had a return on equity of 19.38% and a net margin of 6.80%.The business had revenue of $15.03 billion during the quarter, compared to the consensus estimate of $14.40 billion. During the same period in the prior year, the company earned $0.78 EPS. Pfizer’s revenue for the quarter was up 2.6% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, equities analysts expect that Pfizer Inc. will post 2.94 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Friday, July 24th will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.6%. The ex-dividend date is Friday, July 24th. Pfizer’s dividend payout ratio (DPR) is presently 226.32%.

Hedge Funds Weigh In On Pfizer

A number of institutional investors have recently added to or reduced their stakes in PFE. Bank of New York Mellon Corp boosted its position in Pfizer by 7.4% in the second quarter. Bank of New York Mellon Corp now owns 57,879,546 shares of the biopharmaceutical company’s stock valued at $1,393,739,000 after buying an additional 3,999,646 shares in the last quarter. Prospect Financial Services LLC grew its stake in shares of Pfizer by 48.6% during the second quarter. Prospect Financial Services LLC now owns 10,711 shares of the biopharmaceutical company’s stock worth $258,000 after buying an additional 3,505 shares during the last quarter. Private Advisory Group LLC increased its holdings in shares of Pfizer by 13.3% during the second quarter. Private Advisory Group LLC now owns 254,299 shares of the biopharmaceutical company’s stock worth $6,124,000 after buying an additional 29,858 shares in the last quarter. Focus Partners Advisor Solutions LLC lifted its stake in shares of Pfizer by 19.5% in the 2nd quarter. Focus Partners Advisor Solutions LLC now owns 145,419 shares of the biopharmaceutical company’s stock valued at $3,502,000 after acquiring an additional 23,735 shares during the last quarter. Finally, ABN AMRO Bank N.V. boosted its holdings in shares of Pfizer by 8.6% during the 2nd quarter. ABN AMRO Bank N.V. now owns 54,296 shares of the biopharmaceutical company’s stock valued at $1,307,000 after acquiring an additional 4,298 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.